louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05703282: A Study to Assess the Safety and Pharmacokinetics of AD-104-A
Official title: A Parallel, Open-Label, Single-Dose Administration, Phase 1 Clinical Study to Assess the Safety and Pharmacokinetics of AD-104-A in Healthy Adult Volunteers and Patients With Renal Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hyperlipidemias
Lead sponsor: Addpharma Inc.
Sponsor class: INDUSTRY
First posted: 2023-01-30
Enrollment: 32
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A

Detailed description: The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-104-A in Healthy Adult Volunteers and Patients with Renal Impairment

Eligibility criteria: Inclusion Criteria:

For all subjects

* Adults aged 19 years and older
* Body mass index(BMI) of 18 to 30 kg/m2
* Voluntarily given written informed consent

For renal Impairment subjects

* 30 ≤ eGFR \< 90 mL/min/1.73m\^2

For healthy subjects

* eGFR ≥ 90 mL/min/1.73m\^2

Exclusion Criteria:

* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
* Other exclusions applied

Primary outcomes:
measure: Cmax
timeFrame: pre-dose to 192 hours
measure: AUC
timeFrame: pre-dose to 192 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Jongno-gu
Study officials:
References:
Clinical trial NCT05388682: Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Official title: Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Takayasu Arteritis With Pulmonary Artery Involvement
Percutaneous Transluminal Pulmonary Angioplasty
PAH Targeted Medication
Keywords: Percutaneous transluminal pulmonary angioplasty, Takayasu Arteritis with Pulmonary Artery Involvement
Lead sponsor: Chinese Pulmonary Vascular Disease Research Group
Sponsor class: OTHER
First posted: 2022-05-24
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients diagnosed with Takayasu arteries with pulmonary arteries involvement received either medical or percutaneous transluminal pulmonary angioplasty

Brief summary: 1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement
2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement

Detailed description: At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.

Eligibility criteria: Inclusion Criteria:

* patients diagnosed with Takayasu arteries with pulmonary arteries involvement

Exclusion Criteria:

* Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis

Primary outcomes:
measure: all cause death
timeFrame: 2014/1/1-2042/12/31
measure: mean pulmonary arterial pressure change
timeFrame: 2014/1/1-2042/12/31
measure: pulmonary vascular resistance change
timeFrame: 2014/1/1-2042/12/31
measure: 6MWD change
timeFrame: 2014/1/1-2042/12/31
measure: peak VO2 change
timeFrame: 2014/1/1-2042/12/31
measure: NT-proBNP change
timeFrame: 2014/1/1-2042/12/31
measure: RV/LV change
timeFrame: 2014/1/1-2042/12/31
measure: CI change
timeFrame: 2014/1/1-2042/12/31
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Study officials:
affiliation: Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
name: zhihong Liu, doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02591082: Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
Official title: A Multi-Center, Post-Marketing, Prospective, Observational Study Following Treatment With Intra-Arterial Delivery of Chemotherapeutic Agents Using the RenovoCath™ RC120 Catheter
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatic Neoplasms
Lead sponsor: RenovoRx
Sponsor class: INDUSTRY
First posted: 2015-10-29
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with unresectable or borderline resectable pancreatic cancer.

Brief summary: This is an observational study to assess patient survival and clinical outcomes after the RenovoCath™ RC120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.

Detailed description: This is an observational, registry study to assess patient survival and clinical outcomes of the RenovoCath™ RC120 catheter when used to deliver chemotherapeutic agents to pancreatic tumors. Blood samples will be drawn in a subset of patients to assess the systemic concentration of the chemotherapeutic agent.

The RenovoCath™ RC120 Catheter is an endovascular multi-lumen, two-handled catheter designed to isolate variable segments of arteries supplying the target organ using two slideable, compliant balloons. Upon inflation of the proximal occlusion balloon and the distal occlusion balloon, the catheter may isolate the selected site to specifically deliver radiopaque and therapeutic agents including, but not limited to chemotherapeutic drugs.

Eligibility criteria: Inclusion Criteria:

* 18 years of age
* Diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma confirmed by histology or cytology
* Without current myelotoxicity and with sufficient health status to undergo a catheterization procedure
* Willing to provide informed consent and comply with the required follow-up.

Exclusion Criteria:

* Have received prior chemotherapy and/or radiation therapy within 14 days prior to the first intra-arterial treatment.
* Currently participating in another active drug or device study or registry protocol that would interfere with this study.
* Vulnerable populations: prisoners, pregnant or breastfeeding females.

Primary outcomes:
measure: Survival
timeFrame: 2 Years
Secondary outcomes:
measure: Tumor response
timeFrame: 6 months
Other outcomes:
Locations:
city: San Jose
country: United States
facility: Good Samaritan Hospital
state: California
city: Port Charlotte
country: United States
facility: Fawcett Memorial Hospital
state: Florida
city: Tampa
country: United States
facility: Florida Hospital
state: Florida
city: Bronx
country: United States
facility: Montefiore Hospital
state: New York
city: Greenville
country: United States
facility: East Carolina University
state: North Carolina
Study officials:
affiliation: Chief Medical Officer
name: Ramtin Agah, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06695182: the Real-world Data of Risk Factor and Its Prognosis in PREmature Coronary ARtery DIseAse Study
Official title: the Real-world Data of Risk Factor and Its Prognosis in PREmature Coronary ARtery DIseAse Study (PRE-CARDIA)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Premature Coronary Heart Disease
Keywords: Premature coronary heart disease
Risk factor
aging
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital, Sun Yat-Sen University
First posted: 2024-11-19
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study adopts a single-center, one-arm and historical prospective cohort design, and plans to retrospectively collect the data of patients with metabolic cardiovascular diseases hospitalized in the Department of Cardiovascular Medicine of the First Affiliated Hospital of Sun Yat-sen University from January 2013 to now through the electronic medical record system.

Brief summary: The goal of this observational study is to explore the relationship between biological aging and long-term prognosis of patients with metabolic cardiovascular disease in premature coronary artery disease. The main question\[s\] it aims to answer \[is/are\]:

1. Do patients with premature coronary heart disease have accelerated biological aging?
2. What is the prognosis of accelerated biological aging in patients with premature coronary heart disease?


Eligibility criteria: Inclusion Criteria:

* Male or female inpatients over 18 years old in the Department of Cardiovascular Medicine;
* Patients with one of the following metabolic cardiovascular diseases \[17\]: including diabetes, hypertension, coronary heart disease, heart failure, cerebral infarction, dyslipidemia, obesity and hyperuricemia;
* Those who have corresponding inspection data so as to be able to calculate the biological age;
* Obtaining oral informed consent or signing an informed consent form;

Exclusion Criteria:

·NA

Primary outcomes:
measure: International physical activity questionnaire
timeFrame: Baseline.
measure: Accelerometer
timeFrame: Up to 8 weeks.
measure: Cardiopulmonary test
timeFrame: Up to 8 weeks.
measure: Glucose
timeFrame: Up to 8 weeks.
measure: Hemoglobin A1c (HbA1c)
timeFrame: Up to 8 weeks.
measure: Serum creatinine
timeFrame: Up to 8 weeks.
measure: Lipid
timeFrame: Up to 8 weeks.
measure: Serum uric acid
timeFrame: Up to 8 weeks.
measure: Blood urea nitrogen
timeFrame: Up to 8 weeks.
Secondary outcomes:
measure: Center for Epidemiologic Studies Depression Scale (CES-D)
timeFrame: Up to 8 weeks.
measure: uroQol 5-Dimension 5-Level (EQ-5D-5L)
timeFrame: Up to 8 weeks.
measure: Multidimensional Sports Self-efficacy Scale (MSES)
timeFrame: Up to 8 weeks.
measure: Chinese self-efficacy for exercise scale (SEE-C)
timeFrame: Up to 8 weeks.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03697382: Effect of Daily Steps on Fat Metabolism
Official title: Effect of Daily Ambulatory Activity on the Responses to Acute Aerobic Exercise.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atherosclerosis
Metabolic Syndrome
Lead sponsor: University of Texas at Austin
Sponsor class: OTHER
First posted: 2018-10-05
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Subjects will complete three experimental conditions which include 2 days of reduced step count (2,500, 5,000, and 7,500 steps/day) with 1-hour of exercise at 65% VO2max.
Primary purpose: PREVENTION

Brief summary: Reduced ambulatory activity has been shown to effect the response to a high fat tolerance test (HFTT) after acute exercise. This study will evaluate the effect of varying levels of daily ambulation on response to a HFTT after an acute aerobic exercise bout.


Eligibility criteria: Exclusion Criteria:

* Cardiovascular problems (e.g. pre-existing heart issues, coronary artery disease, hypertension, etc.)
* Respiratory problems
* Musculoskeletal problems that prevent prolonged sitting or exercise
* Obesity
* Susceptibility to fainting
* Pregnancy

Primary outcomes:
measure: 6-Hour Plasma Triglyceride Area Under the Curve
timeFrame: 6-hours
Secondary outcomes:
measure: 6-Hour Plasma Insulin Area Under the Curve
timeFrame: 6-hours
measure: 6-Hour Plasma Glucose Area Under the Curve
timeFrame: 6-hours
Other outcomes:
Locations:
city: Austin
country: United States
facility: University of Texas at Austin Human Performance Laboratory
state: Texas
Study officials:
affiliation: University of Texas at Austin
name: Heath Burton, M.S.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Texas at Austin
name: Edward F Coyle, Ph.D.
role: STUDY_DIRECTOR
References:
citation: Burton HM, Coyle EF. Daily Step Count and Postprandial Fat Metabolism. Med Sci Sports Exerc. 2021 Feb 1;53(2):333-340. doi: 10.1249/MSS.0000000000002486.
Clinical trial NCT01227382: Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods
Official title: Prospective Evaluation of the Accuracy of Spybite Biopsy Forceps for the Tissue Diagnosis of Lesion of the Pancreatobiliary System. ( Part of the "The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Treatment of Pancreaticobiliary Disorders" Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Accuracy of Tissue Diagnosis
Bile Duct Stricture
Pancreatic Duct Stricture
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2010-10-25
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The investigators are evaluating the use of a SpyBite biopsy forceps for tissue diagnosis when compared to standard biopsy techniques.

Detailed description: The participants will undergo an Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy and evaluation of a bile duct or pancreatic duct stricture with three different types of techniques for biopsy: SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps.

Eligibility criteria: Inclusion Criteria:

1. Subjects is 18 years or older
2. Scheduled to undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) wiht cholangioscopy and/or pancreatoscopy at the University of Florida Gainesville Florida as medically indicated.
3. Lesion of the pancreatobiliary system that requires tissue sampling as medically indicated
4. Subject myst be able to give informed consent

Exclusion Criteria:

1. Any contraindication to Endoscopic Retrograde Cholangiopancreatography (ERCP)
2. The subject is unable to give informed consent

Primary outcomes:
measure: Percentage of Participants With Accurate Diagnoses of Cancer
timeFrame: up to 7 days after the procedure
Secondary outcomes:
measure: Procedure Technical Success
timeFrame: day 1
measure: Total Procedure Time
timeFrame: 120 minutes
measure: Total Cholangioscopy Time
timeFrame: 60 minutes
measure: Cholangioscopy Visualization Time
timeFrame: 30 minutes
measure: Sampling Times for Each Device
timeFrame: 15 minutes
measure: Adverse Events
timeFrame: 24 hours
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: Shands at UF Ensopcopy
state: Florida
Study officials:
affiliation: University of Flordia
name: Peter Draganov, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Draganov PV, Chauhan S, Wagh MS, Gupte AR, Lin T, Hou W, Forsmark CE. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc. 2012 Feb;75(2):347-53. doi: 10.1016/j.gie.2011.09.020.
Clinical trial NCT02901782: The Application of Personalized Titanium Plate in the Bone Tumors Around the Knee
Official title: Personalized Titanium Plate Improves Clinical Outcome in Microwave Ablation of Bone Tumors Around the Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Tumors
Keywords: Knee
Titanium Plate
Lead sponsor: Guangzhou General Hospital of Guangzhou Military Command
Sponsor class: OTHER
Collaborators: name: Medical Center of Assessment, Prevention and Treatment of Bone & Joint Diseases, Guangdong, China
name: The First Affiliated Hospital of Guangzhou Medical University
First posted: 2016-09-15
Enrollment: 12
Sex: ALL
Minimum age (years): 5
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Microwave ablation of bone tumors is time-consuming and usually results in postoperative fractures. Hence the investigators designed and fabricated a titanium plate customized to the patient's bone structures for fixation after the removal of tumorous tissue, to improve the clinical outcomes of microwave ablation.

Detailed description: 3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.

Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of primary malignant bone tumors in the distal femur or proximal tibia according to the preoperative biopsy.
2. Malignant soft tissue tumor invading distal femur or proximal tibia.
3. The patients have the opportunity of limb salvage and treatment of microwave-induced hyperthermia in situ and reconstruction with internal fixation.

Exclusion Criteria:

1. Distant metastasis.
2. Benign tumor.
3. Metastatic tumor around the knee.
4. No indication of limb salvage.
5. Malignant soft tissue tumor without bone invasion.
6. Recrudescent tumors.

Primary outcomes:
measure: Musculoskeletal Tumor Society score
timeFrame: An average of 29 months
measure: Mean maximum flexion of the knee
timeFrame: An average of 29 months
measure: The six degrees of freedom of the gait
timeFrame: An average of 29 months
Secondary outcomes:
measure: Mean operation time
timeFrame: Time when the operation was begun
Other outcomes:
Locations:
Study officials:
affiliation: Hospital of Orthopedics, Guangzhou General Hospital of Guangzhou Military Command, 111 Liuhua Road, Guangzhou 510010, China
name: Yu Zhang, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01718782: Laryngeal Mask Ambu Aura Once vs. Supreme in Children
Official title: Ventilation With Laryngeal Mask Ambu Aura Once vs. Supreme in Children
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Apnea
Keywords: laryngeal mask, leakage pressure, ventilation
Lead sponsor: Medical University Innsbruck
Sponsor class: OTHER
First posted: 2012-10-31
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is determine safety and efficiency of mechanical ventilation in children with two different types of single use laryngeal masks (Ambu AuraOnce vs. LMA Supreme). The main interest is leakage pressure of oropharynx and stomach. The null hypothesis is that leakage pressures of Ambu AuraOnce and LMA Supreme are equivalent. The alternative hypothesis is that there is a difference in leakage pressure.

Detailed description: Before starting surgery patients will be anesthetised and airway managed either with LMA Ambu AuraOnce or Supreme. Ventilation parameters, stomach inflation, and hemodynamic parameters will be measured.

Eligibility criteria: Inclusion Criteria:

* Children aged 1-10 years
* ASA I - III
* Elective procedure in general anaesthesia
* Parental informed consent

Exclusion Criteria:

* Non fasting patient
* Body mass index \> 35 kg/m2
* Cervical spine pathologies or peripheral neurologic deficiences
* Malformations of upper airway or head
* Anamnestic hiatus hernia or esophageal reflux
* Status post operation of stomach or esophagus
* Recurrent respiratory infection or obstructive airway disease
* Non elective procedure

Primary outcomes:
measure: Leakage pressure [cmH2O]
timeFrame: 1min
Secondary outcomes:
measure: Efficient ventilation [mL],
timeFrame: 3min
measure: tidal volume [mL],
timeFrame: 3 minutes
measure: stomach insufflation [yes or no]
timeFrame: 3 minutes
Other outcomes:
Locations:
city: Innsbruck
country: Austria
facility: University Hospital Innsbruck
state: Tirol
Study officials:
affiliation: University Hospital Innsbruck, Department of Anaesthesia + Intensive Care
name: Peter Paal, MD,DESA,EDIC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02477982: Influence of Obesity on Propofol Pharmacokinetics During Cardiopulmonary Bypass
Official title: Influence of Obesity on Propofol Pharmacokinetics During Cardiac Surgeries Using Cardiopulmonary Bypass: Derivation of a Pharmacokinetic Model
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Keywords: Propofol
Cardiopulmonary Bypass
Pharmacokinetics
Obesity
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2015-06-23
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing elective cardiac surgery using Cardiopulmonary bypass with moderate hypothermia (defined as core body temperature of 28-32oC).

Brief summary: The primary objective of this study is to develop a descriptive and predictive pharmacokinetics model propofol disposition during cardiopulmonary bypass (CPB) in obese and lean patients.

Detailed description: Anaesthesia maintenance upon initiation of CPB will be achieved by propofol (1%) bolus (1 mg/kg TBW) immediately followed by 2 mg/kg TBW/hr infusion that will be continued till weaning from CPB. During CPB an additional propofol bolus doses can be administered to prevent awareness according to the clinical judgment of the responsible anaesthesiologist. Any additional doses given and their timings will be recorded.

Blood samples of 2 ml each will be collected from the arterial line of CPB machine until the end of CPB then from sub-clavin arterial catheter routinely inserted in such surgeries. Sampling process will follow the following schedule; at baseline prior to dosing, followed by samples at 1, 3, 5,7 min after the propofol bolus dose, then every 20 minutes during propofol infusion, just before discontinuation of the propofol infusion and at 1, 3, 5, 7, 10, 20, 30, 60 minutes after the end of infusion. In addition, just before any rescue propofol dose administration, an unscheduled sample will be withdrawn

Eligibility criteria: Inclusion Criteria:

* BMI ≤ 25 kg/m2 or ≥ 30 kg/m2.
* Propofol based maintenance of anaesthesia during CPB.

Exclusion Criteria:

* Pregnant women or lactating mothers.
* Renal (serum creatinine concentration\>1.5 or creatinine Cl ≤ 30 ml/min) or hepatic disorders (total bilirubin \>1.5 or ≥ 2 fold increase in alanine transferase (ALT) or aspartate transferase (AST).
* Systemic infections.
* Hypoalbuminemia (defined as albumin \<3.5 gm/dL).
* Known history of alcohol or drug abuse.
* Administration of aspirin on the day of surgery or warfarin within 7 days preceding surgery

Primary outcomes:
measure: Clearance (Cl/)
timeFrame: intraoperative
measure: volume of distribution of first compartment (V1)
timeFrame: intraoperative
measure: Clearance from first to second compartment (Q1)
timeFrame: intraoperative
measure: volume of distribution of second compartment (V1)
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: